S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Combined Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) Is Active for Relapsed and Refractory Patients with CLL.
William G. Wierda,Stefan Faderl,Susan O'Brien,Jorge E. Cortes,Alessandra Ferrajoli,Francis J. Giles,Michael Andreff,Charles Koller,Hagop M. Kantarjian,Michael J. Keating +9 more
TL;DR: This phase II study combined A with FCR (CFAR) to improve response rates and survival in previously treated patients and found all patients achieving CR were negative for residual disease in bone marrow by 2-color flow cytometry.
Journal ArticleDOI
Randomized Phase II Study of Combined Epigenetic Therapy: Decitabine Vs. Decitabine and Valproic Acid in MDS and AML
Jean Pierre J. Issa,Ryan J. Castoro,Farhad Ravandi-Kashani,Stefan Faderl,Xuelin Huang,Elihu H. Estey,Gautam Borthakur,Gail Morris,Guillermo Garcia-Manero,Hagop M. Kantarjian +9 more
TL;DR: Preliminary analysis of this randomized study suggests that adding VPA to DAC only marginally improves response rate and time to first response and has no impact on survival in MDS and AML.
Journal ArticleDOI
A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor GX15-070 Administered Intravenously (IV) Every 3 Weeks to Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL).
Susan O'Brien,Thomas J. Kipps,Stefan Faderl,Michael Crump,Michael J. Keating,Blanche Anderson,Claudia Soho,Jan Bole,Ruth Turner,Jean Viallet,Bruce D. Cheson +10 more
TL;DR: Single agent GX15-070 exhibits dose dependent biological activity in previously treated CLL with documented induction of apoptosis and improvement in hematological parameters at well tolerated doses.
Journal ArticleDOI
Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML).
Guillermo Garcia-Manero,Allen S. Yang,Francis J. Giles,Stefan Faderl,Farhad Ravandi,Jorge E. Cortes,Willie Newsome,Jean Pierre J. Issa,Tracy-Ann Patterson,Marja Dubay,Zuomei Li,Hagop M. Kantarjian,Robert E. Martell +12 more
TL;DR: The combination of azacitidine with MGCD0103 is safe in patients with advanced AML/MDS and the combination has encouraging safety, PK, and clinical activity profiles.
Journal ArticleDOI
The addition of all-trans retinoic acid to chemotherapy may not improve the outcome of patient with NPM1 mutated acute myeloid leukemia
Aziz Nazha,Carlos E. Bueso-Ramos,Eli Estey,Eli Estey,Stefan Faderl,Susan O'Brien,Michael H. Fernandez,Martin Nguyen,Charles Koller,Emil J. Freireich,Miloslav Beran,Sherry Pierce,Michael J. Keating,Jorge E. Cortes,Hagop M. Kantarjian,Farhad Ravandi +15 more
TL;DR: The addition of ATRA to intensive chemotherapy did not affect the overall outcome of patients with AML regardless of NPM1 mutation status, and the overall survival, event- free survival, and relapse-free survival were similar among patients who received ATRA.